Bioleaders Corporation

Korea Research Institute of Bioscience and Biotechnology

The Industry & Academic Cooperation in Chungnam National University

Korea Institute of Science and Technology

Kookmin University

Chungbuk National University Industry Academic Cooperation

Chul Joong Kim

Haryoung Poo

Moon-Hee Sung

Ji Yeon Kim

Young-Ki Choi

Hyun Soo Kim

Kwang Soo Kim

Seung-Pyo Hong

Yong Taik Lim

Il Ha Lee

Il Han Lee

Moon Hee Sung

Long Chun Xu

Eun Kim

Dong Jin Jeong

Young Suk Kim

Kwang Soon Shin

Dai-Won Yoo

Sang-Mu Shim

The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.

Adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles

The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (&#x3b3;-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient. The composition containing poly-gamma-glutamic acid as an effective ingredient according to the present invention, is effective for use as an animal feedstuff additive or a pharmaceutical agent for preventing influenza virus infection and various viral diseases as well as a pharmaceutical composition and a functional food to promote human health.

Composition for preventing virus infection comprising poly-gamma-glutamic acid

The present invention relates to a fusion protein in which a myostatin mature protein is fused to a multimer of myostatin-derived antigenic peptide Myo-2, a surface expression vector containing a polynucleotide encoding the fusion protein, a recombinant microorganism transformed with the vector, and a feedstuff additive or a pharmaceutical composition containing the microorganism as an effective ingredient. The feedstuff additive or pharmaceutical composition according to the present invention can be used for muscle development and regulation of muscle growth in livestock and poultry, as well as for preventing and treating muscle-wasting diseases and degenerative diseases such as muscular dystrophy, muscular atrophy and the like. In addition, the transformed strain shows the same effect even if the strain itself after culture thereof is directly used, and thus it is very economical.

Surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin, and microorganism transformed by thereof

Disclosed herein are an aldolase gene promoter and the use thereof, more particularly, disclosed are a promoter of aldolase gene derived from, having a base sequence of SEQ ID NO: 1, an expression vector containing said promoter, and a recombinant microorganism transformed with said expression vector. The recombinant microorganism transformed with the expression vector containing the disclosed promoter can effectively express a target protein on the surface thereof, and thus will be useful as vaccine vehicles and the like.

Constitutive strong promoter and use thereof

Disclosed are alphavirus-based expression vectors expressing env, gag, pro, and/or pol genes of HIV-1, their transcripts, and transformed host cells. The present invention describes the expression of the Gag, Env, Pol, and/or Pro Proteins using the above expression vectors, and HIV-like particles (HIVLPs) composed of the above recombinant proteins. The virus-like particles (VLPs) of the present invention, as the mature and infective particles, are very useful as an antigen for a diagnostic kit for HIV infection as well as for a vaccine composition for prevention of HIV infection.

HIV-like particles and the use thereof

Growing community of inventors

Daejeon, South Korea

Chul Joong Kim